Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
157 hedge funds and large institutions have $1.4B invested in Akero Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 59 increasing their positions, 45 reducing their positions, and 54 closing their positions.
239% more call options, than puts
Call options by funds: $42M | Put options by funds: $12.4M
31% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 45
5.15% more ownership
Funds ownership: 102.72% → 107.88% (+5.2%)
13% less funds holding
Funds holding: 181 → 157 (-24)
43% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 54
52% less capital invested
Capital invested by funds: $2.9B → $1.4B (-$1.5B)
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$70.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$51.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$40.5M |
| 4 |
Morgan Stanley
New York
|
+$33M |
| 5 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$54.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$39.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$32.9M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$28.1M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$26M |
AKRO Hedge Fund Activity: Q4 2023 in Review
157 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q4 2023, worth a combined $1.4B — down 52% from $2.9B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of AKRO and 31 opened new positions — a net loss of 23 holders — while 45 trimmed existing stakes and 59 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $70.9M. The largest seller was Fidelity Investments, cutting an estimated $54.2M.
- 157 institutional investors held Akero Therapeutics (AKRO) as of Q4 2023, down from 181 in Q3 2023.
- Funds reported $1.4B of Akero Therapeutics stock for Q4 2023, down 52% quarter-over-quarter.
- 31 funds opened new Akero Therapeutics positions in Q4 2023 and 54 closed out, a net change of -23 holders.
- The largest Akero Therapeutics buyer in Q4 2023 was RTW Investments, an estimated $70.9M added.
- The largest Akero Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $54.2M sold.
Based on aggregated 13F filings for Q4 2023.